Renovorx, inc.RNXT.US Overview
US StockHealthcare
(No presentation for RNXT)
RNXT Overall Performance
RNXT AI Analysis & Strategy
RNXT Recent Performance
0.07%
Renovorx, inc.
0.81%
Avg of Sector
-1.14%
S&P500
RNXT PowerScanner
RNXT Key Information
RNXT Valuation Metrics
RNXT Earnings Table
RNXT Profile
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.